XtalPi advances hair loss drug program into IND-enabling studies

• XtalPi moved a proprietary hair-loss drug program into IND-enabling studies, starting pharmacology, safety, and CMC work for an IND filing.
• Program targets a lactate-autophagy pathway to reactivate quiescent hair follicle stem cells, aiming for a differentiated mechanism versus minoxidil.
• In a DHT-induced mouse model, a candidate matched 5% topical minoxidil’s hair-growth score at 1/100 of its concentration.
• Development used AI-guided design, free-energy perturbation modeling, robotic synthesis, and testing to optimize potency, skin penetration, and topical safety.
• Move into drug development builds on two AI-developed scalp-care ingredients already commercialized, extending the company’s hair-health portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN62932) on October 02, 2026, and is solely responsible for the information contained therein.